Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Forecasted to Earn FY2024 Earnings of ($1.73) Per Share

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Research analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a note issued to investors on Wednesday, August 14th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will earn ($1.73) per share for the year, up from their prior estimate of ($1.77). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($1.87) per share.

Several other equities analysts also recently commented on the company. StockNews.com raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th. Truist Financial restated a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $12.75.

Marinus Pharmaceuticals Stock Performance

NASDAQ:MRNS opened at $1.34 on Monday. The firm has a market capitalization of $73.61 million, a PE ratio of -0.51 and a beta of 1.13. The company has a quick ratio of 2.93, a current ratio of 3.07 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $11.26. The firm has a 50-day moving average price of $1.32 and a 200 day moving average price of $4.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. The business had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. During the same quarter in the prior year, the company posted ($0.61) EPS.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several large investors have recently made changes to their positions in MRNS. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals in the second quarter worth about $28,000. SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $34,000. AQR Capital Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $64,000. Finally, Values First Advisors Inc. grew its holdings in shares of Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares in the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.